2QG Stock Overview
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Quantum Genomics Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.12 |
| 52 Week High | €0.19 |
| 52 Week Low | €0.071 |
| Beta | 0.66 |
| 1 Month Change | 15.53% |
| 3 Month Change | 31.64% |
| 1 Year Change | -23.23% |
| 3 Year Change | -96.74% |
| 5 Year Change | -97.55% |
| Change since IPO | -97.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2QG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.2% | -3.2% | 2.0% |
| 1Y | -23.2% | -25.4% | 5.9% |
Return vs Industry: 2QG exceeded the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 2QG underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 2QG volatility | |
|---|---|
| 2QG Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2QG's share price has been volatile over the past 3 months.
Volatility Over Time: 2QG's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 3 | Jean-Philippe Milon | www.quantum-genomics.com |
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.
Quantum Genomics Société Anonyme Fundamentals Summary
| 2QG fundamental statistics | |
|---|---|
| Market cap | €4.60m |
| Earnings (TTM) | -€3.17m |
| Revenue (TTM) | €19.80k |
232.4x
P/S Ratio-1.5x
P/E RatioIs 2QG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2QG income statement (TTM) | |
|---|---|
| Revenue | €19.80k |
| Cost of Revenue | €1.44m |
| Gross Profit | -€1.42m |
| Other Expenses | €1.75m |
| Earnings | -€3.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | -7,169.57% |
| Net Profit Margin | -16,018.12% |
| Debt/Equity Ratio | 622.2% |
How did 2QG perform over the long term?
See historical performance and comparison